PF-AtlasClinical Trials › NCT06502379

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

AZD8965 · Phase 1

Registry ID
NCT06502379
Phase
Phase 1
Status
Completed
Drug / intervention
AZD8965
Sponsor
AstraZeneca
Start
2024-08-02

About this trial

AZD8965 is evaluated in NCT06502379, a Phase 1 idiopathic pulmonary fibrosis study sponsored by AstraZeneca. Current status: Completed.

View NCT06502379 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT06502379 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.